Table 3.
Competing risk survival analysis according to clinical characteristics, tumor stage and protein expression*
| Variables ∆ | Cause-specific Cox regression | ||
|---|---|---|---|
| Univariate analysis (n = 64) | RRª | 95%CI | p-value |
| Age b (> 44 vs. ≤44 years) | 9.46 | 1.21–74.05 | 0.03 |
| Tumor stage (II-IV vs. I) | 15.17 | 0.68–6.70 | < 0.001 |
| Histopathological grade (G2-G3 vs. G1) | 0.51 | 0.01–0.29 | 0.19 |
| MMP-2 tumor | – | – | < 0.000ß |
| MMP-2 stroma | 3.91 | 1.17–13.02 | 0.03 |
| MMP-9 tumor | 0.19 | 0.04–0.90 | 0.04 |
| MMP-9 stroma | 0.19 | 0.05–0.65 | 0.01 |
| MMP-14 tumor | 3.57 | 0.43–29.90 | 0.24 |
| MMP-14 stroma | 7.11 | 0.88–57.58 | 0.07 |
| TIMP-1 tumor | 0.45 | 0.06–3.56 | 0.45 |
| TIMP-1 stroma | 2.30 | 0.67–7.89 | 0.19 |
| TIMP-2 tumor | 3.19 | 0.90–11.55 | 0.07 |
| TIMP-2 stroma | 8.67 | 1.15–65.27 | 0.04 |
| VEGF-A tumor | 3.23 | 0.90–11.55 | 0.07 |
| VEGF-A stroma | 3.77 | 0.80–117.73 | 0.09 |
*The expression was analyzed based on the percentage of stained cells and categorized by the ROC curve; ∆The first category is the reference aRR = relative risk. ß All the women showing higher expressions of tumoral MMP-2 entered died from the disease before the analysis began, so the relative risk could not be assessed